Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.

Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets.

Pieris has established a diverse pipeline of Anticalin therapeutics for a number of different indications and has R&D collaborations with Roche, Daiichi Sankyo, the Sanofi Group and others.

Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.